Efficacy of IOP reduction and safety of Eybelis ophthalmic solution 0.002% switched from Prostaglandin analog.
Not Applicable
- Conditions
- glaucoma or ocular hypertension
- Registration Number
- JPRN-UMIN000035193
- Lead Sponsor
- Inouye Eye Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 77
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with aphakic eye or implanted IOL in the eye (history of cataract surgery), Patients with cataract surgery scheduled (within the last 6 months) Patients with some corneal abnormality or other diseases which may interfere with accurate IOP measurement using Goldmann applanation tonometer Patients with a history of corneal refractive surgery Patients with active extraocular disease, inflammation or infection in the eye(s) or eyelid(s) Patients with allergy to the ingredients used in the present study Pregnant, lactating women or women who may be pregnant, and women who wish to be pregnant or can not conduct appropriate contraception during the study period
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method